



THE CANADIAN JOURNAL OF
Neurological Sciences
LE JOURNAL CANADIEN DES
Sciences Neurologiques

AN INTERNATIONAL JOURNAL / UN JOURNAL INTERNATIONAL

EDITORIALS

- 117 Next Steps
Douglas Zochodne
- 118 NeuroAIDS in West Africa: A Full Circle
Christopher Power
- 120 Time for a Population Based Approach to Multiple Sclerosis Care
Luanne Metz

COMMENTARIES

- 121 The Voice of Neurosurgeons: Doctors' Non-Medical Writing
Mark Bernstein
- 124 The Fictional Neurologist
Andrew Kirk

REVIEW ARTICLES

- 126 Canadian Association of Neurosciences Review: Prion Protein and Prion Diseases: The Good and the Bad
Malcolm J. Gains, Andrea C. LeBlanc
- 146 Human Tonotopic Maps and their Rapid Task-Related Changes Studied by Magnetic Source Imaging
Isamu Ozaki, Isao Hashimoto

ORIGINAL ARTICLES

- 154 Memory Performance in HIV/AIDS - A Prospective Case Control Study
Francis E. Odiase, Olubunmi A. Ogunrin, Adesola A. Ogunniyi
- 160 Factors Associated with Health-Related Quality of Life in Multiple Sclerosis
Wilma M. Hopman, Helen Coo, Cathy M. Edgar, Evelyn V. McBride, Andrew G. Day, Donald G. Brunet
- 167 Health Status and Health Care Utilization of Multiple Sclerosis in Canada
Sheri L. Pohar, C. Allyson Jones, Sharon Warren, Karen V.L. Turpin, Kenneth Warren
- 175 Prevalence of Multiple Sclerosis in First Nations People of Alberta
Lawrence W. Svenson, Sharon Warren, Kenneth G. Warren, Luanne M. Metz, Scott B. Patten, Donald P. Schopflocher
- 181 The Incidence Trends of Primary Brain Tumors in Saskatchewan from 1970 to 2001
F. Pirouzmand, V. Sadanand
- 187 Headache During Gestation: Evaluation of 1101 Women
Elians M. Melhado, Jayme A. Maciel Jr., Carlos A.M. Guerreiro
- 193-242 (See Contents Pages)

NEUROIMAGING HIGHLIGHT

- 243 Submitted by: *P.N. Sylaja, M. Goyal, T. Watson, M.D. Hill*

PEER REVIEWED LETTERS (See contents pages)

MEMORIAM (See contents pages)

CORRESPONDENCE (See contents pages)



John Edmeads



Colloid Cyst

**42nd
Annual
Congress**

presented by the

**Canadian Neurological
Sciences Federation
(formerly CCNS)**

June 19-22, 2007
Edmonton, Alberta

Real accuracy. Real results.

No other radiosurgery system for non-invasive brain surgery has the accuracy, stability and efficacy of Leksell Gamma Knife[®]. Or the proof to back it up.

With over 2,000 peer-reviewed published articles, Leksell Gamma Knife[®] has an unmatched body of clinical evidence. Our accuracy is also unmatched, with a recent study demonstrating an average accuracy of 0.15 mm and a clinical accuracy (including imaging) of 0.48mm.

Read it for yourself. Get the Leksell Gamma Knife[®] Accuracy brochure at www.elekta.com/proof.





THE CANADIAN JOURNAL OF

Neurological Sciences

LE JOURNAL CANADIEN DES

Sciences Neurologiques

EDITORIALS

- 117 Next Steps
Douglas Zochodne
- 118 NeuroAIDS in West Africa: A Full Circle
Christopher Power
- 120 Time for a Population Based Approach to Multiple Sclerosis Care
Luanne Metz

COMMENTARIES

- 121 The Voice of Neurosurgeons: Doctors' Non-Medical Writing
Mark Bernstein
- 124 The Fictional Neurologist
Andrew Kirk

REVIEW ARTICLES

- 126 Canadian Association of Neurosciences Review: Prion Protein and Prion Diseases: The Good and the Bad
Malcolm J. Gains, Andrea C. LeBlanc
- 146 Human Tonotopic Maps and their Rapid Task-Related Changes Studied by Magnetic Source Imaging
Isamu Ozaki, Isao Hashimoto

ORIGINAL ARTICLES

- 154 Memory Performance in HIV/AIDS - A Prospective Case Control Study
Francis E. Odiase, Olubunmi A. Ogunrin, Adesola A. Ogunniyi
- 160 Factors Associated with Health-Related Quality of Life in Multiple Sclerosis
Wilma M. Hopman, Helen Coo, Cathy M. Edgar, Evelyn V. McBride, Andrew G. Day, Donald G. Brunet
- 167 Health Status and Health Care Utilization of Multiple Sclerosis in Canada
Sheri L. Pohar, C. Allyson Jones, Sharon Warren, Karen V.L. Turpin, Kenneth Warren
- 175 Prevalence of Multiple Sclerosis in First Nations People of Alberta
Lawrence W. Svenson, Sharon Warren, Kenneth G. Warren, Luanne M. Metz, Scott B. Patten, Donald P. Schopflicher

- 181 The Incidence Trends of Primary Brain Tumors in Saskatchewan from 1970 to 2001
F. Pirouzmand, V. Sadanand
- 187 Headache During Gestation: Evaluation of 1101 Women
Elians M. Melhado, Jayme A. Maciel Jr., Carlos A.M. Guerreiro
- 193 Ataxia and the Role of Antigliadin Antibodies
D. Wong, M. Dwinell, M. Schulzer, M. Nimmo, B.R. Leavitt, S.D. Spacey
- 197 Endoscopic Versus Microsurgical Resection of Third Ventricle Colloid Cysts
Ron T. Grondin, Walter Hader, M. Elizabeth MacRae, Mark G. Hamilton
- 208 Possible Anticipation in Hereditary Spastic Paraplegia Type 4 (SPG4)
P. Leema Reddy, William K. Seltzer, Raji P. Grewal
- 211 SPG4 Founder Effect in French Canadians with Hereditary Spastic Paraplegia
Inge A. Meijer, Nicolas Dupré, Bernard Brais, Patrick Cossette, St Onge J, Marie-France Rioux, Melanie Benard, Guy A. Rouleau
- 215 Motor Neuron Degeneration in a 20-Week Male Fetus: Spinal Muscular Atrophy Type 0
Harvey B. Sarnat, Cynthia L. Trevenen
- 221 Neurocardiogenic Syncope: Frequency and Consequences of its Misdiagnosis as Epilepsy
Colin B. Josephson, Susan Rahey, R. Mark Sadler
- 225 Evaluating the Development of a SPECT Protocol in a Canadian Epilepsy Unit
J.G. Burneo, W. Vezina, J. Romsa, B.J. Smith, R.S. McLachlan
- 230 Treating Newly Diagnosed Epilepsy: The Canadian Choice
J.G. Burneo, R.S. McLachlan
- 237 Treatment of Secondary Tonsillar Herniation by Lumboperitoneal Shunt Revision
Fred C. Lam, Matthew B. Wheatley, Vivek Mehta

NEUROIMAGING HIGHLIGHT

- 243 Submitted by: *P.N. Sylaja, M. Goyal, T. Watson, M.D. Hill*

PEER REVIEWED LETTERS

- 245 Malignant Teratoid/Rhabdoid Tumour: Long-Term Survival
Barbara J. Fisher, Kristopher E.B. Dennis, Lee-Cyn Ang



THE CANADIAN JOURNAL OF
Neurological Sciences
LE JOURNAL CANADIEN DES
Sciences Neurologiques

Editor-in-Chief/Rédacteur en chef
Douglas W. Zochodne CALGARY, AB

Associate Editors/Rédacteurs associés
J. Max Findlay EDMONTON, AB
Michael Shevell MONTREAL, QC
G. Bryan Young LONDON, ON

Past Editors/Anciens rédacteurs en chef
James A. Sharpe TORONTO, ON
Robert G. Lee CALGARY, AB
Robert T. Ross WINNIPEG, MB
(Emeritus Editor, Founding Editor)

Editorial Board/Conseil Scientifique
Timothy J. Benstead HALIFAX, NS
J. Gregory Cairncross CALGARY, AB
Richard Desbiens QUEBEC CITY, QC
Ian Fleetwood HALIFAX, NS
David Fortin SHERBROOKE, QC
Hans-Peter Hartung DUSSELDORF, GERMANY
Alan C. Jackson KINGSTON, ON
Jack Jhamandas EDMONTON, AB
Daniel Keene OTTAWA, ON
Douglas Kondziolka PITTSBURGH, PA, USA
Terence Myles CALGARY, AB
Robert Hammond LONDON, ON
Guy Rouleau MONTREAL, QC
Paul Steinbok VANCOUVER, BC
Oksana Suchowersky CALGARY, AB
Brian Toyota VANCOUVER, BC
Brian Weinschenker ROCHESTER, MN, USA
Samuel Wiebe CALGARY, AB
Elaine Wirrell CALGARY, AB

SECTION EDITORS/CONSEIL DE RÉDACTION

Neuroimaging Highlight/Neuroimagerie

Mark Hudon CALGARY, AB
Richard Farb TORONTO, ON

Neuropathological Conference/Conférence sur la neuropathologie

Robert Hammond LONDON, ON

Book Review/Critiques de livres

Andrew Kirk SASKATOON, SK

Electronic Editor/Rédacteur d'électronique

Daniel Keene OTTAWA, ON

Journal Staff

Dan Morin, *Chief Executive Officer*
Maggie McCallion, *Designer/Production Coordinator*
Cindy Leschyshyn, *Editorial Coordinator*

Publications Committee/Comité de Rédaction

Samuel Wiebe CALGARY, AB
David Fortin SHERBROOKE, QC
Asuri Prasad LONDON, ON
Richard McLachlan LONDON, ON

The official journal of: / La Revue officielle de:

The Canadian Neurological Society
La Société Canadienne de Neurologie
The Canadian Neurosurgical Society
La Société Canadienne de Neurochirurgie
The Canadian Society of Clinical Neurophysiologists
La Société Canadienne de Neurophysiologie Clinique
The Canadian Association of Child Neurology
L'Association Canadienne de Neurologie Pédiatrique

The permanent secretariat for the four societies and the Canadian Congress of Neurological Sciences is at:
Le secrétariat des quatre associations et du Congrès Canadien des Sciences Neurologiques est situé en permanence à:
7015 Macleod Trail SW, Suite 709, Calgary AB, Canada T2H 2K6.

The Canadian Journal of Neurological Sciences is published quarterly. The annual subscription rate for Individuals are: C\$90 (Canada), US\$90 (USA), and US\$95 (elsewhere). Subscription rates for Institutions are: C\$100 (Canada), US\$100 (USA), and US\$105 (elsewhere). Resident, intern and student rates are available. See www.cjns.org for details. Single copies C\$25 each plus postage and handling. All manuscripts and communications should be sent to: Canadian Journal of Neurological Sciences, 709 - 7015 Macleod Trail SW, Calgary, AB Canada T2H 2K6. Telephone (403) 229-9575; Fax (403) 229-1661. E-mail: journal@cjns.org; Website: www.cjns.org COPYRIGHT © 2007 by THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES INC. All rights reserved. No part of this journal may be reproduced in any form without the prior permission of The Canadian Journal of Neurological Sciences. Mailed under Publications Mail Agreement no: 40007777; PAP Registration no: 09824. Postage paid at Calgary, Alberta. This journal is indexed by *Abstracts on Hygiene and Communicable Diseases, Aquatic Sciences and Fisheries Abstracts, ASCA-Automatic Subject Citation Alert, Biological Abstracts, BIOBASE, BIOSIS, Chemical Abstracts Current Awareness in Biological Sciences, Current Contents (Clinical Medicine and Life Sciences), Dental Index, e-psyche, Excerpta Medica, Index Medicus, Index to Scientific Reviews, Journal Watch Neurology, Laboratory Hazards Bulletin, Leisure, Recreation and Tourism Abstracts, MEDLINE, Neurosciences Citation Index, Nutrition Abstracts and Reviews, Nutrition Research Newsletter, Pharmacoeconomics and Outcome News, PsycInfo, Psychological Abstracts, Reactions Weekly, Referativnyi Zhurnal, Review of Medical and Veterinary Mycology, Science Citation Index, Weed Abstracts.*

Le Journal Canadien des Sciences Neurologiques est publié trimestriellement. L'abonnement annuel est de 90 \$C (non-membres au Canada); 90 \$É-U (États Unis) et 95 \$É-U (ailleurs); l'abonnement annuel pour les institutions est de 100 \$C (non-membres au Canada); 100 \$É-U (États Unis) et 105 \$É-U (ailleurs); Internes, résidents, fellows pré et post doctoral voir www.cjns.org pour détails. Copie simple: 25 \$C plus affranchissement et manutention. Toutes les communications et les manuscrits doivent être adressés à Journal Canadien des Sciences Neurologiques, 709 - 7015 Macleod Trail SW, Calgary, AB Canada T2H 2K6. Téléphone (403) 229-9575; Fax (403) 229-1661. E-mail journal@cjns.org; Website: www.cjns.org DROITS D'AUTEUR © 2007: THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES INC. Tous droits réservés. Aucune partie de ce Journal ne peut être reproduite, sous quelque forme que ce soit, sans la l'autorisation du Journal Canadien des Sciences Neurologiques. Posté sous poste-publications: numéro de convention 40007777; numéro d'enregistrement PAP09824. Port payé à Calgary, Alberta. Le Journal est cité et indexé dans *Abstracts on Hygiene and Communicable Diseases, Aquatic Sciences and Fisheries Abstracts, ASCA-Automatic Subject Citation Alert, Biological Abstracts, BIOBASE, BIOSIS, Chemical Abstracts Current Awareness in Biological Sciences, Current Contents (Clinical Medicine and Life Sciences), Dental Index, e-psyche, Excerpta Medica, Index Medicus, Index to Scientific Reviews, Journal Watch Neurology, Laboratory Hazards Bulletin, Leisure, Recreation and Tourism Abstracts, MEDLINE, Neurosciences Citation Index, Nutrition Abstracts and Reviews, Nutrition Research Newsletter, Pharmacoeconomics and Outcome News, PsycInfo, Psychological Abstracts, Reactions Weekly, Referativnyi Zhurnal, Review of Medical and Veterinary Mycology, Science Citation Index, Weed Abstracts.*

Advertising representative/Représentant de publicité:

Brett Windle, *Corporate Development Coordinator*
Tel (403) 229-9575 Fax (403) 229-1661
E-mail: brett-windle@cnsfederation.org

Printer/Imprimeur:

Sundog Printing Limited, 1311 Ninth Avenue SW
Calgary, Alberta T3C 0H9

ISSN 0317 - 1671

We acknowledge the assistance of the Government of Canada through the Publications Assistance Program towards our mailing costs. 

IS THIS HOW YOUR PATIENT FEELS?



TIME FOR ADDITIONAL SUPPORT

- ⚓ # 1 dispensed oral cannabinoid[†]
- ⚓ 25 years of clinical experience in Canada
- ⚓ On formulary across Canada except P.E.I.[‡]

[†]Refers to 0.5 mg and 1 mg strengths. Limited coverage in Saskatchewan.

[‡]CESAMET® (nabilone) is indicated for the management of severe nausea and vomiting associated with cancer chemotherapy.

[‡]CESAMET® is contraindicated in patients with known sensitivity to marijuana or other cannabinoid agents, and in those with a history of psychotic reactions.

[‡]CESAMET® should be used with extreme caution in patients with severe liver dysfunction and those with a history of non-psychotic emotional disorders.


The most frequently observed adverse reactions to nabilone and their incidences reported in the course of clinical trials were: drowsiness (66%), vertigo (58.8%), psychological high (38.8%) and dry mouth (21.6%). Please consult prescribing information for full warnings, precautions, adverse events and administration.¹

[†]IMS Health Canada: Canadian CompuScript Audit, Monthly data, August 2005-September 2006, Total Dispensed Prescriptions

VALEANT
Valiant Canada / limitée / Limited

Customer Service 1-800-361-4261

Reference: 1. Cesamet Product Monograph, September 2004.



nabilone
CESAMET[®]
Symptom Control

Treat your hypertensive patients with the power of MICARDIS.:

- ▲ Powerful 24-hour BP reductions shown, $p < 0.0001$ including the early morning hours (6:00 AM-11:59 AM), $p < 0.0001$ ^{2†}
- ▲ Longest half-life of all AT₁ receptor blockers^{3-8§}
- ▲ Simple, flexible, once-daily dosing^{3‡}

ONTARGET

▲ The ONTARGET clinical trial program investigates ARB and ACE therapy in more than 31,000 patients.

▲ ONTARGET investigates MICARDIS (telmisartan) and ramipril, alone or in combination, in the prevention of cardiovascular morbidity and mortality in patients at high risk for cardiovascular complications.

▲ Boehringer Ingelheim is committed to cardiovascular protection research.

MICARDIS is not indicated to reduce cardiovascular or cerebrovascular morbidity and mortality, or to improve renal outcomes.

MICARDIS
 TELMISARTAN 80mg AT₁ RECEPTOR BLOCKER
 GOOD MORNING. MICARDIS.




Boehringer
 Ingelheim

COMMITTED TO CARDIOVASCULAR
 PROTECTION RESEARCH
 www.boehringer-ingelheim.ca



MICARDIS. Demonstrated Powerful BP Reductions Measured from MORNING to MORNING¹



Demonstrated significantly greater 24-hour ABPM reduction vs. placebo, $p < 0.05$ ^{1‡}

MICARDIS (telmisartan) is indicated for the treatment of mild to moderate essential hypertension and may be used alone or in combination with thiazide diuretics.² The most common adverse events vs. placebo were headache (8.0% vs. 15.6%), upper respiratory tract infection (6.5% vs. 4.6%), dizziness (3.6% vs. 4.6%), pain (3.5% vs. 4.3%), fatigue (3.2% vs. 3.3%), back pain (2.7% vs. 0.9%), diarrhea (2.6% vs. 1.0%) and sinusitis (2.2% vs. 1.9%).³ If pregnancy is detected, MICARDIS should be discontinued as soon as possible.¹ In patients who are volume-depleted by diuretic therapy, dietary salt restrictions, dialysis, diarrhea or vomiting, symptomatic hypotension may occur after initiation of therapy with MICARDIS.³

[†] 6-week, multinational, multicenter, randomized, double-blind, double-dummy, parallel group study comparing MICARDIS 80 mg and Losartan 50 mg with placebo arm. MICARDIS: 80 mg mean 24-hour SBP vs. placebo = -13.3 mmHg vs. -1.8 mmHg. DBP = -8.4 mmHg vs. -0.5 mmHg. $p < 0.05$.

[‡] 14-week, multicenter, prospective, randomized, open-label, blinded endpoint, parallel group, forced-titration study of MICARDIS and Atilace[®] in patients with confirmed ambulatory hypertension. Mean 24-hour SBP = -14.3 mmHg vs. -9.7 mmHg, $p < 0.0001$. Morning (06:00 AM-11:59 AM) SBP = -14.3 mmHg vs. -6.7 mmHg, $p < 0.0001$.

[§] Comparative clinical significance is unknown.

[‡] Being available in MICARDIS 40 mg and MICARDIS PLUS 80/12.5 mg HCTZ.

MICARDIS is a registered trademark used under license by Boehringer Ingelheim (Canada) Ltd.

Boehringer Ingelheim: Committed to cardio and vascular protection research

>31,000
patients enrolled
in the **ONTARGET**
two-part study
programme^{1,2}

MICARDIS® (telmisartan) is indicated for the treatment of mild to moderate essential hypertension and may be used alone or in combination with thiazide diuretics.

The most common adverse events vs. placebo were headache (8.0% vs. 15.6%), upper respiratory tract infection (6.5% vs. 4.6%), dizziness (3.6% vs. 4.6%), pain (3.5% vs. 4.3%), fatigue (3.2% vs. 3.3%), back pain (2.7% vs. 0.9%), diarrhea (2.6% vs. 1.0%) and sinusitis (2.2% vs. 1.9%).

If pregnancy is detected, MICARDIS® should be discontinued as soon as possible. In patients who are volume-depleted by diuretic therapy, dietary salt restriction, dialysis, diarrhea or vomiting, symptomatic hypotension may occur after initiation of therapy with MICARDIS®.

MICARDIS® is not indicated to reduce cardiovascular or cerebrovascular morbidity and mortality, or to improve renal outcomes.

1. The ONTARGET/TRANSCEND Investigators. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. *American Heart Journal* 2004;148 vol.1:52-61. 2. Data on file, Boehringer Ingelheim (Canada) Ltd.

MICARDIS® is a registered trademark used under license by Boehringer Ingelheim (Canada) Ltd. PROFESS® is a registered trademark used under license by Boehringer Ingelheim GmbH, Germany. Aggrenox® is a registered trademark used under license by Boehringer Ingelheim (Canada) Ltd. Altace® is a registered trademark of sanofi-aventis Canada. Plavix® is a registered trademark of sanofi-aventis Canada.



Current Ongoing International Cardio and Vascular Trials:

	ONTARGET	TRANSCEND	PROFESS®
Number of Patients Internationally	25,622 ²	5,926 ²	20,333 ²
Number of Canadian Patients	2,519 ²	426 ²	1,549 ²
Number of International Centres	730 ^{1,2}	730 ^{1,2}	674 ²

ONTARGET Cardiovascular Mortality and Morbidity Trial

- ▶ ONTARGET investigates MICARDIS® (telmisartan) and Altace® (ramipril), alone or in combination, in the prevention of cardiovascular morbidity and mortality in patients at high risk for cardiovascular complications.¹
- ▶ Inclusion Criteria:¹
 - ▶ Male or female, age ≥55 years
 - ▶ At high risk of developing a CVD event, with a history of one of the following:
 - Coronary artery disease
 - Peripheral arterial occlusive disease (PAOD)
 - Cerebrovascular event
 - Diabetes mellitus with evidence of end-organ disease

TRANSCEND Cardiovascular Mortality and Morbidity Trial

- ▶ TRANSCEND investigates MICARDIS® vs. placebo for the prevention of cardiovascular morbidity and mortality in patients at high risk for cardiovascular complications and who are intolerant to angiotensin-converting enzyme inhibitors.¹

PROFESS® Stroke Trial

- ▶ PROFESS® investigates patients with known prior ischemic strokes. Patients will receive at random either MICARDIS® or placebo. Both groups will also receive at random either Aggrenox® (ASA/extended-release dipyridamole) or Plavix® (clopidogrel).²

COMMITTED TO CARDIO AND
VASCULAR PROTECTION RESEARCH



www.boehringer-ingelheim.ca

For brief prescribing information see page A-33

PrAGGRENOX® PROVIDES

STRONG DEFENSE AGAINST A SECOND STROKE


- AGGRENOX® prevented **twice** as many strokes vs. ASA alone^{1,2,3*}
 - 22.1% additional stroke protection over ASA ($p=0.008$)^{2†}
 - 36.8% greater stroke protection vs. placebo ($p<0.001$)^{2†}
- Proven safety profile²
- ASA/extended release dipyridamole is recommended as **first-line** secondary stroke prevention therapy in:
 - Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy⁴
 - European Stroke Initiative (EUSI)⁵
 - UK Royal College Physician Guidelines⁶

* Randomized, double-blind, placebo-controlled trial, 6,602 patients with history of TIA or ischemic stroke. AGGRENOX® 50 mg ASA + 400 mg extended release dipyridamole per day (b.i.d. dosing) n=1,650, ASA 50 mg per day (25 mg b.i.d.) n=1,649, placebo n=1,649, extended release dipyridamole 400 mg per day (200 mg b.i.d.) n=1,654. For every 1,000 patients treated for two years, AGGRENOX® prevented 58 strokes vs. only 29 for ASA, compared to placebo.^{1,2†}

† Percentage of patients experiencing a stroke within two years: AGGRENOX® 9.5%, ASA 12.5%, placebo 15.2%.²

AGGRENOX® is indicated for the prevention of stroke in patients who have had a previous stroke or a transient ischemic attack (TIA). The overall discontinuation rate due to adverse events was 27.8% for AGGRENOX®, 23.2% for ASA, and 23.7% for placebo. AGGRENOX® is contraindicated in patients with known allergy to nonsteroidal anti-inflammatory drug products; patients with the syndrome of asthma, rhinitis and nasal polyps; and in patients with hypersensitivity to dipyridamole, ASA, or any of the other product components. AGGRENOX® contains approximately 23 mg sucrose and 106 mg of lactose per maximum recommended daily dose. Patients with rare hereditary problems of fructose intolerance and/or galactose intolerance (e.g. galactosemia) should not take this medicine. If a patient is to undergo elective surgery, consideration should be given to discontinue AGGRENOX® 10 days prior to surgery, to allow for the reversal of effect. The use of AGGRENOX® may increase the risk of bleeding such as skin haemorrhage, gastrointestinal bleeding and intracerebral haemorrhage. The addition of other antiplatelet agents (e.g. Clopidogrel, Ticlopidine) to AGGRENOX® may further increase the risk of serious bleeding and is not recommended. Due to the ASA component of AGGRENOX® should be avoided in patients with severe hepatic insufficiency or severe renal failure, avoided in patients with a history

References: 1. Diener HC, et al. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. *Journal of the Neurological Sciences* 1996;143:1-13. 2. AGGRENOX® Product Monograph. Boehringer Ingelheim (Canada) Ltd. July 2006. 3. Diener HC, et al. European Stroke Prevention Study 2. Efficacy and Safety Data. *Journal of the Neurological Sciences* 1997;151:S1-S77. 4. Albers GW, Amarenco P, Easton DJ, Sacco RL, Teal P. Antithrombotic and Thrombolytic Therapy for Ischemic Stroke. Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *CHEST* 2004;126:483S-512S.



of active peptic ulcer disease, and used with caution in patients with inherited or acquired bleeding disorders, nursing mothers, patients taking selective serotonin reuptake inhibitors (SSRIs) or corticosteroids, or in patients who consume three or more alcoholic drinks per day. AGGRENOX® should not be used in paediatric patients or during the third trimester of pregnancy. AGGRENOX® has a vasodilatory effect and should be used with caution in patients with severe coronary artery disease (e.g. unstable angina or recently sustained myocardial infarction). The most common adverse events with AGGRENOX® was headache (39.2% vs. 33.8% for ASA and 32.9% for placebo), dyspepsia (18.4% vs. 18.1% for ASA, and 16.7% for placebo), abdominal pain (17.5% vs. 15.9% for ASA and 14.5% for placebo), nausea (16.0% vs. 12.7% for ASA and 14.1% for placebo), and diarrhea (12.7% vs. 6.8% for ASA and 9.8% for placebo). When headache occurred it was particularly evident in the first month of therapy: 8.9% of patients discontinued due to headache, 66% of these discontinued within the first month. Discontinuation rates due to headache were 2.8% and 2.1% in the placebo and ASA group respectively. Consult Prescribing Information for complete details.

5. European Stroke Initiative (EUSI) Executive Committee, and EUSI Writing Committee. EUSI Recommendations for Stroke Management – Update 2003. *Cerebrovascular Dis* 2003;16:311-337. 6. Royal College of Physicians of London. National Clinical Guidelines for Stroke, June 2004. © AGGRENOX is a registered trademark of Boehringer Ingelheim (Canada) Ltd.



Challenging the benchmark in secondary stroke prevention^{1,4,5,6}

Neuropathic Pain Scalded From Within

LYRICA®

Powerful Pain Relief



LYRICA (pregabalin) is an analgesic indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) and postherpetic neuralgia (PHN).

LYRICA is contraindicated in patients who are hypersensitive to pregabalin or to any ingredient in the formulation or component of the container.

The most commonly observed adverse events (twice the rate as that seen with placebo) were dose related for PHN and DPN patients in the recommended dose range of 150 mg/day to 600 mg/day; dizziness (9-37%), somnolence (6.1-24.7%), peripheral edema (6.1-16.2%) and dry mouth (1.9-14.9%).

Dosage reduction is required in patients with renal impairment as LYRICA is primarily eliminated by renal excretion.

Please see Prescribing Information for complete Warnings and Precautions, Dosage and Administration and patient selection criteria.

† A 12-week, multicentre, randomized, double-blind, placebo-controlled study in 338 patients with neuropathic pain (DPN [n=249] or PHN [n=89]), resulting in a significant difference from placebo in the flexible dose range 150-600 mg/day ($p < 0.05$, week 2 and $p < 0.01$, weeks 3-12), and the fixed dose of 600 mg/day ($p < 0.05$, week 1 and $p < 0.01$, weeks 2-12).
‡ A 13-week, multicentre, double-blind, placebo-controlled trial in 368 patients with PHN. A significant difference in pain reduction was shown over placebo for all doses: 150 mg/day, 300 mg/day, and 600 mg/day at week 1, $p < 0.001$. Sleep interference was improved at all time points (weeks 1 to 13 and endpoint) for the three doses evaluated ($p < 0.01$ vs. placebo).

Powerful. Fast Onset. Sustained Relief.

- Powerful pain reduction ($\geq 50\%$ pain reduction) shown in 48.2% of neuropathic pain patients (DPN or PHN); 24.2% for placebo, $p < 0.001$ ^{†,‡}
- Rapid neuropathic pain relief shown in patients with PHN as early as Week 1^{3,4*}
- Sustained neuropathic pain relief demonstrated over 3 months^{2†}
- Rapid and sustained improvement in pain-related sleep interference observed in patients with PHN^{3,4*}



Working for a healthier world™

© 2007
Pfizer Canada Inc.
Orléans, Québec
H9J 2M5



* LYRICA used under license
LYRICA is a registered trademark of
C. P. Pharmaceuticals International C.V.
Pfizer Canada Inc., Lesene

LYRICA PREGABALIN

Fast onset. Sustained relief.

For full prescribing information see pages A-24 to A-27

MS PATIENTS HAVE HIGH HOPES



TYSABRI is indicated as monotherapy (i.e., single disease-modifying agent) for the treatment of patients with the relapsing-remitting form of multiple sclerosis (MS) to reduce the frequency of clinical exacerbations, to decrease the number and volume of active brain lesions identified on magnetic resonance imaging (MRI) scans and to delay the progression of physical disability. TYSABRI is generally recommended in MS patients who have had an inadequate response to, or are unable to tolerate, other therapies for multiple sclerosis.¹

Safety and efficacy in patients with chronic progressive multiple sclerosis, and in geriatric and pediatric patients, have not been established.¹

Efficacy and safety of TYSABRI for a treatment duration beyond 2 years has not been determined.¹

TYSABRI should be used by physicians who have sufficient knowledge of multiple sclerosis and who have familiarized themselves with the efficacy/safety profile of TYSABRI.¹

TYSABRI is contraindicated in patients who are hypersensitive to this drug or to any ingredient in the formulation or component of the container; patients who have or have had progressive multifocal leukoencephalopathy (PML); patients who are immunocompromised, including those immunocompromised due to immunosuppressant or antineoplastic therapies, or immunodeficiencies (HIV, leukemias, lymphomas, etc.).¹

GIVE THEM STRENGTH TO HELP REACH THEM

The strength of TYSABRI has demonstrated powerful benefits in clinical trials.

Over 2 years TYSABRI vs. placebo (n = 627 vs. n = 315)¹:

- **68% reduction in annualized relapse rate ($p < 0.001$) (0.24 vs. 0.73)**
- **42% reduction in the risk of disability progression (EDSS increase sustained for 12 weeks) ($p < 0.001$)[†] (17% vs. 29%)**
- **Significant improvement in all MRI endpoints ($p < 0.001$)[‡]**
- **Significant slowing of brain atrophy in the second year of treatment (BPF) ($p = 0.004$)[§]**
- **Significant improvement in cognitive function (PASAT3) ($p = 0.005$)[¶]**

TYSABRI is a selective adhesion molecule inhibitor.

* Comparative clinical significance has not been established.

† Disability progression defined as a ≥ 1.0 point increase from baseline EDSS of ≥ 1.0 or a ≥ 1.5 point increase from baseline EDSS of 0.

‡ Reduction in mean number of Gd-enhancing lesions vs. placebo (0.1 vs. 1.2), reduction in mean number of new or newly enlarging T2-hyperintense lesions vs. placebo (1.9 vs. 11.0), percentage of patients free of either type of lesion vs. placebo (Gd-enhancing 97% vs. 72%, T2-hyperintense 57% vs. 15%) and median change in volume of T2-hyperintense lesions vs. placebo (-9.4% vs. 8.8%).

§ TYSABRI 0.24% vs. placebo 0.43% reduction in brain volume measured by Brain Parenchymal Function.

¶ Paced Auditory Serial Addition Test 3.

Treatment with TYSABRI has been associated with an increased risk of progressive multifocal leukoencephalopathy (PML). PML can cause disability or death. Healthcare professionals should monitor patients on TYSABRI for any new sign or symptom that may be suggestive of PML. TYSABRI dosing should be withheld immediately at the first sign or symptom suggestive of PML.¹

Patients who are prescribed TYSABRI should enroll in the Tysabri Care Program.^{TM1}

The most common serious adverse drug reactions were infections (3.2% vs. 2.6% placebo), acute hypersensitivity reactions (1.1% vs. 0.3%), depression (1.0% vs. 1.0%) and cholelithiasis (1.0% vs. 0.3%).¹

REFERENCE:

1. TYSABRI Product Monograph, 2006.




NEW
EVERY
4-WEEKS
TYSABRITM
(natalizumab)

Strength you can believe in

TYSABRI, The Tysabri Care Program and ELAN are trademarks of Elan Pharma International Ltd.
BIOGEN IDEC is a trademark of Biogen Idec MA Inc.

© 2006 Biogen Idec MA Inc.

LES PATIENTS ATTEINTS DE SEP ONT DE GRANDS ESPOIRS



TYSABRI est indiqué en monothérapie (c'est-à-dire comme agent d'un traitement de fond utilisé seul) pour le traitement de la forme rémittente de la sclérose en plaques (SEP) afin de diminuer la fréquence des poussées cliniques, de réduire le nombre et le volume des lésions cérébrales actives décelées aux examens d'imagerie par résonance magnétique (IRM) et de ralentir la progression de l'incapacité. TYSABRI est généralement recommandé chez les patients atteints de SEP qui ne répondent pas bien aux autres traitements de la SEP ou ne peuvent les tolérer¹.

On n'a pas établi l'innocuité ni l'efficacité du produit chez les patients atteints de sclérose en plaques chronique progressive, ni chez les patients en pédiatrie et en gériatrie¹.

On n'a pas déterminé l'innocuité ni l'efficacité de TYSABRI dans un traitement durant plus de deux ans¹.

Seuls les médecins qui connaissent suffisamment la sclérose en plaques et qui se sont familiarisés avec l'efficacité et l'innocuité du médicament peuvent utiliser TYSABRI¹.

TYSABRI est contre-indiqué chez les patients qui présentent une hypersensibilité à ce médicament, à l'un des composants du produit ou du contenant; chez les patients qui sont, ou ont déjà été, atteints de leucoencéphalopathie multifocale progressive (LMP); chez les patients immunodéprimés, y compris ceux qui le sont par suite de l'administration d'immunosuppresseurs ou d'agents antinéoplasiques et ceux qui sont atteints d'immunodéficience (infection par le VIH, leucémies, lymphomes, etc.)¹.

DONNEZ-LEUR DE LA PUISSANCE POUR LES AIDER À LES ATTEINDRE

La puissance de TYSABRI a permis de montrer de grands bienfaits dans les essais cliniques.

Deux ans avec TYSABRI vs placebo (n = 627 vs n = 315)¹:

- Réduction de **68 %** du nombre de poussées par année ($p < 0,001$) (0,24 vs 0,73)
- Réduction de **42 %** du risque de progression de l'incapacité (augmentation de la cote EDSS soutenue pendant 12 semaines) ($p < 0,001$)[†] (17 % vs 29 %)
- Amélioration significative de tous les paramètres de l'IRM ($p < 0,001$)[‡]
- Ralentissement significatif de l'atrophie cérébrale durant la deuxième année de traitement (FPC) ($p = 0,004$)[§]
- Amélioration significative de la fonction cognitive (PASAT3) ($p = 0,005$)[¶]

TYSABRI est un inhibiteur sélectif de la molécule d'adhésion.

* La portée clinique comparative n'a pas été établie.

† La progression de l'incapacité se définit par l'augmentation de $\geq 1,0$ point de la cote EDSS par rapport à des valeurs de départ de $\geq 1,0$ ou par l'augmentation de $\geq 1,5$ point par rapport à une valeur de départ de 0.

‡ Réduction du nombre moyen de lésions qui prennent le gadolinium vs placebo (0,1 vs 1,2), réduction du nombre moyen de lésions hyperintenses en T2, nouvelles ou nouvellement en progression, vs placebo (1,9 vs 11,0), pourcentage de patients ne présentant pas ces types de lésions vs placebo (prenant le gadolinium 97 % vs 72 %, hyperintenses en T2 57 % vs 15 %) et changement médian du volume des lésions hyperintenses en T2 vs placebo (-9,4 % vs 8,8 %).

§ Réduction de 0,24 % avec TYSABRI vs de 0,43 % avec le placebo du volume du cerveau mesuré d'après la fonction parenchymateuse du cerveau.

¶ Test d'additions en série en réponse à des directives vocales (*Paced Auditory Serial Addition Test 3*).

On a associé le traitement par TYSABRI à une augmentation du risque de leucoencéphalopathie multifocale progressive (LMP). La LMP peut entraîner une incapacité ou le décès. Les professionnels de la santé doivent surveiller les patients qui prennent TYSABRI au cas où de nouveaux signes ou symptômes signaleraient l'apparition de la LMP. Il faut interrompre l'administration de TYSABRI dès l'apparition du premier signe ou symptôme qui laisse croire à une LMP¹.

Les patients à qui on a prescrit TYSABRI doivent adhérer au Programme de soins Tysabri^{MC1}.

Les effets indésirables graves le plus souvent signalés étaient les suivants : infections (3,2 % vs 2,6 % placebo), réactions aiguës d'hypersensibilité (1,1 % vs 0,3 %), dépression (1,0 % vs 1,0 %) et cholélithiase (1,0 % vs 0,3 %)¹.

RÉFÉRENCE :

1. Monographie de TYSABRI, 2006.

biogen idec

élan

CCPP*

TYSABRI, Programme de soins Tysabri et Elan sont des marques de commerce d'Elan Pharma International Ltd.

Biogen Idec est une marque de commerce de Biogen Idec MA Inc.

© Biogen Idec MA Inc., 2006

NOUVEAU
TOUTES LES
4 SEMAINES

TYSABRI^{MC}
(natalizumab)

Une puissance en laquelle vous pouvez croire

Minimally Invasive Spine Therapies

Kyphon commits to restoring spinal function with minimally invasive therapies through continuous research, innovative product development and advanced professional education.

To date, over 250,000 patients are successfully treated with **Balloon Kyphoplasty**, a minimally invasive procedure to reduce vertebral compression fractures and improve patient quality of life.

To learn more about Balloon Kyphoplasty, call 1-877-459-7466

Kyphon Canada
9861 Leslie Street
Richmond Hill, Ontario
L4B3Y4
T 403-240 2454
F 403-246-4304
canada@kyphon.com
www.kyphon.com



MOB006-ENC-01

KYPHON
AHEAD OF THE CURVE™

Canadian Neurological Sciences Federation 42nd Annual Congress

Novo Nordisk Canada Inc.
Co-developed Satellite Symposium -
The Changing Paradigm of
Intracerebral Hemorrhage
(rFVIIa ICH Trial Results)

Wednesday, June 20, 2007

12:30 p.m. - 2:00 p.m.

Shaw Conference Centre, Edmonton, Alberta



Learning Objectives

1. Participants will learn about current treatment options in ICH
2. Participants will learn and discuss the impact of current and future clinical trials on ICH
3. Participants will review and discuss the current role of rFVIIa as a treatment option for ICH
4. Participants will learn about rFVIIa's mechanism of action



Canadian Neurological Society Société canadienne de neurologie

This program is an Accredited Group Learning Activity as defined by the Maintenance of Certification Program of the Royal College of Physicians & Surgeons of Canada. This program has been reviewed and co-developed by the Canadian Neurological Society.



novo nordisk®



CANADIAN
NEUROLOGICAL
SCIENCES
FEDERATION
FÉDÉRATION
DES SCIENCES
NEUROLOGIQUES
DU CANADA

**Are you a Canadian
neurologist,
neurophysiologist,
neurosurgeon or
neurology/neurosurgery
resident?**

**Then the Canadian Neurological Sciences Federation
(CNSF) has a member society for you!**

The four member societies are:

- ◆ Canadian Neurological Society (CNS)
- ◆ Canadian Neurosurgical Society (CNSS)
- ◆ Canadian Society of Clinical Neurophysiologists (CSCN)
- ◆ Canadian Association of Child Neurology (CACN)

Benefits of membership include:

- *Canadian Journal of Neurological Sciences (CJNS) subscription*, both print and online. CJNS is a highly respected international neurological sciences medical journal.
- **Significantly reduced registration fees** for the annual congress.
- The **Annual Membership Directory**, available on-line to members only
- **Maintenance of Certification and Continuing Medical Education (CME)** opportunities through the annual congress.
- The CNSF newsletter **Neuro News**
- **Access to grants, awards and fellowships**
- **Residents** receive these benefits for a bargain-priced annual fee of \$35.

For membership information,
call us at (403) 229-9544;
e-mail: info@cnsfederation.org
or check out the CNSF website
at www.cnsfederation.org

Partners in the Management of Acute Stroke Care



ACTIVASE[®]
ALTEPLASE
A RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR
IN ACUTE ISCHEMIC STROKE



Roche

We Innovate Healthcare






Mark Hamilton
• CNSF President
• CJNS President
• CNSS Past President



Garth Bray
• CNSF Vice-President
• CJNS Vice-President
• CNS



Brian Wheelock
• CNSF Vice-President
• CJNS Vice-President
• CNSS




Joseph Dooley
• CNSF Board Member
• CJNS Board Member
• CACN President



Douglas Zochodne
• CJNS Editor-in-Chief



Jerome Yager
• CNSF Board Member
• CJNS Board Member
• CACN Vice-President



Derek Fewer
• CNSF Board Member
• CJNS Board Member
• CNSS President



J. Max Findlay
• CNSF Board Member
• CJNS Board Member
• CNSS Vice-President




Andrew Kirk
• CNSF Board Member
• CJNS Board Member
• CNS President



Sam Wiebe
• Publications Committee
Chair




Richard Desbiens
• CNSF Board Member
• CJNS Board Member
• CNS Vice-President



George Elleker
• CNSF Board Member
• CJNS Board Member
• CSCN President



Manouchehr Javidan
• CNSF Board Member
• CJNS Board Member
• CSCN Vice-President



Morris Freedman
• CNSF Board Member
• CJNS Board Member
• CNSF Past President



John Stewart
• CNSF Scientific Program
Committee Chair
• CNS Chair




Carmela Tartaglia
• CNSF Residents' Rep
• CJNS Residents' Rep
• CNS



Dan Morin
• CNSF Board Member
• CJNS Board Member
• CNSF CEO



Sue Brien
• CNSF Professional
Development Committee Chair
• CNSS Accreditor



Charles Tator
• CBANHC Chair
• CNSS

Legend:

CNSF - Canadian Neurological Sciences Federation; CJNS - Canadian Journal of Neurological Sciences; CNS - Canadian Neurological Society; CNSS - Canadian Neurosurgical Society; CSCN - Canadian Society of Clinical Neurophysiologists; CACN - Canadian Association of Child Neurology; CBANHC - Canadian Brain and Nerve Health Coalition